HURA vs MRK vs BMY vs AZN

For growth investors, AstraZeneca PLC (AZN) is the stronger pick with 8.

6% revenue growth year-over-year, versus -0. 2% for Bristol-Myers Squibb Company (BMY). Merck & Co. , Inc. (MRK) offers the better valuation at 15. 6x trailing P/E (22. 2x forward), making it the more compelling value choice. Analysts rate TuHURA Biosciences, Inc. (HURA) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Merck & Co.

, Inc. (MRK) is the cheapest at 15. 6x versus AstraZeneca PLC at 26. 7x. On forward P/E, Bristol-Myers Squibb Company is actually cheaper at 8. 5x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: AstraZeneca PLC wins at 0. 78x versus Merck & Co. , Inc. 's 1. 04x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Merck & Co.

, Inc. (MRK) delivered a total return of +68. 5%, compared to -97. 4% for TuHURA Biosciences, Inc. (HURA). Over 10 years, the gap is even starker: AZN returned +281. 3% versus HURA's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Merck & Co.

, Inc. (MRK) is the lower-risk stock at 0. 25β versus TuHURA Biosciences, Inc. 's 3. 31β — meaning HURA is approximately 1220% more volatile than MRK relative to the S&P 500. On balance sheet safety, TuHURA Biosciences, Inc. (HURA) carries a lower debt/equity ratio of 2% versus 3% for Bristol-Myers Squibb Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AstraZeneca PLC (AZN) is pulling ahead at 8.

6% versus -0. 2% for Bristol-Myers Squibb Company (BMY). On earnings-per-share growth, the picture is similar: AstraZeneca PLC grew EPS 190. 7% year-over-year, compared to 8. 0% for Merck & Co. , Inc.. Over a 3-year CAGR, AZN leads at 9. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus 0. 0% for TuHURA Biosciences, Inc. — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 36. 2% versus 0. 0% for HURA. At the gross margin level — before operating expenses — AZN leads at 81. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, AstraZeneca PLC (AZN) is the more undervalued stock at a PEG of 0. 78x versus Merck & Co. , Inc. 's 1. 04x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Bristol-Myers Squibb Company (BMY) trades at 8. 5x forward P/E versus 22. 2x for Merck & Co. , Inc. — 13. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BMY: 15. 9% to $62. 60.

In this comparison, BMY (4.

6% yield), MRK (2. 9% yield), AZN (1. 9% yield) pay a dividend. HURA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Merck & Co.

, Inc. (MRK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 25), 2. 9% yield, +160. 5% 10Y return). TuHURA Biosciences, Inc. (HURA) carries a higher beta of 3. 31 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MRK: +160. 5%, HURA: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: HURA is a small-cap quality compounder stock; MRK is a large-cap deep-value stock; BMY is a mid-cap deep-value stock; AZN is a large-cap quality compounder stock. MRK, BMY, AZN pay a dividend while HURA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.